Lexeo Therapeutics, Inc. (LXEO) SEC Filings & Earnings Calls
EquiReason read 16 Lexeo Therapeutics, Inc. SEC filings in the last 12 months. Latest: 8-K on 2026-09-29 — Completion of acquisition of Mantle Therapeutics Inc. for upfront consideration of $5.3M cash and $3M in Lexeo common stock, plus contingent payments up to $13M (additional cash $1.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
- Market cap
- 229.7M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 9 Nov, in 16 days
Every filing, read
last 12 months · SECWhat happened, the numbers inside, guidance and risks. The original is one click away.
29 Sep 20268-K · 2.01, 3.02Completion of acquisition of Mantle Therapeutics Inc. for upfront consideration of $5.3M cash and $3M in Lexeo common stock, plus contingent payments up to $13M (additional cash $1M and milestone payments up to $12M over 12 years).acquisitionopen
Risks flagged
Milestone payments are contingent and not guaranteed; no obligation for Lexeo to devote specific resources beyond commercially reasonable efforts.
“Merger Agreement does not require Lexeo to devote any particular level of resources to development or commercialization beyond commercially reasonable efforts.”
22 Sep 20268-K · 1.01, 8.01Lexeo Therapeutics announced entry into a merger agreement to acquire Mantle Therapeutics Inc. Also announced 22 participants enrolled in CLARITY-FA study.being acquiredopen
Figures in the filing · each found in the filing text
| CLARITY-FA study participants | 22 |
Risks flagged
Merger execution risk; integration of Mantle Therapeutics.
“entry into the Merger Agreement...to acquire Mantle Therapeutics Inc.”
12 Aug 20268-K · 2.02, 8.01Cash, cash equivalents and investments $234M; Research and Development expenses $19M (+29% y/y); General and Administrative expenses $9M (-44% y/y)earningsopen
Figures in the filing · each found in the filing text
| Cash, cash equivalents and investments · Q2-2026 | $234M | |
| Research and Development expenses · Q2-2026 | $19M | +29% y/y |
| General and Administrative expenses · Q2-2026 | $9M | -44% y/y |
| Net loss · Q2-2026 | $-26M | -1% y/y |
Risks flagged
Pre-revenue clinical-stage biotech with no approved products; dependent on clinical trial success and regulatory approvals.
“Clinical stage genetic medicine company; no revenue; net loss $25.9M.”
Clinical trial execution risk: LX2006 pivotal trial enrollment and data readout in 2027; LX2020 data in Q4 2026.
“Topline data expected in second half of 2027; 12-month data update for LX2020 in Q4 2026.” · word for word
12 Aug 202610-QLexeo Therapeutics reported Q2 2026 net loss of $46.1 million, initiated pivotal trial for LX2006, and maintained cash runway into 2028.earningsopen
Figures in the filing · each found in the filing text
| Net loss · H1-2026 | $-46M | |
| Accumulated deficit · 2026-06-30 | $426M | |
| Cash, cash equivalents, and investments in U.S. Treasury securities · 2026-06-30 | $234M |
Risks flagged
Clinical trial failure risk
“Our business is dependent on our ability to advance our current and future product candidates through preclinical studies and clinical trials, obtain marketing approval and ultimately commercialize them. If we are unable to or experience significant delays in doing so, our business will be materially harmed.” · word for word
Capital need risk
“We will require substantial future capital in order to complete planned and future clinical development for our lead product candidates, preclinical development for our other product candidates, and potential commercialization of these product candidates, if any are approved.” · word for word
Regulatory uncertainty risk
“Because gene therapy is novel and the regulatory landscape that governs any product candidates we may develop is rigorous, complex, uncertain and subject to change, we cannot predict with certainty the geographic areas in which we could obtain regulatory approval nor the time and cost of obtaining regulatory approval, if we receive it at all, for any product” · word for word
11 May 20268-K · 2.02, 8.01Lexeo Therapeutics reports Q1 2026 results and clinical updates: LX2006 Phase I/II interim data shows statistically significant improvement in mFARS scores vs natural history; LX2020 positive interim data; SUNRISE-FA2 pivotal protocol submiopen
Figures in the filing · each found in the filing text
| Research & Development Expenses · Q1-2026 | $16M | -9% y/y |
| General & Administrative Expenses · Q1-2026 | $7M | -60% y/y |
| Net Loss · Q1-2026 | $-20M | -38% y/y |
| Cash, cash equivalents, and investments in marketable securities · 2026-03-31 | $228M |
Risks flagged
Clinical-stage company with no approved products; dependent on trial success.
“All programs are clinical or preclinical; no revenue.”
Regulatory risk: awaiting FDA feedback on pivotal trial protocol.
“Awaiting final FDA feedback on SUNRISE-FA2 protocol.”
Cash burn: net loss $20.2M in Q1 2026; runway into 2028 but no revenue.
“Net loss $20.2M; cash $227.6M.”
11 May 202610-QNet loss $-20M; Accumulated deficit $-400M; Cash, cash equivalents, and investments in U.S. Treasury securities $228Mopen
Figures in the filing · each found in the filing text
| Net loss · Q1-2026 | $-20M | |
| Accumulated deficit · 2026-03-31 | $-400M | |
| Cash, cash equivalents, and investments in U.S. Treasury securities · 2026-03-31 | $228M |
Risks flagged
Preclinical safety signal for LX2006
“In one of our preclinical studies of LX2006, we observed four cases of hepatocellular carcinoma, or HCC, in wild-type mice at 10 months post-treatment.” · word for word
No approved products or revenue
“We have no products approved for commercialization and have never generated any revenue from product sales.” · word for word
Regulatory and development risk for gene therapy
“Because gene therapy is novel and the regulatory landscape that governs any product candidates we may develop is rigorous, complex, uncertain and subject to change” · word for word
Capital needs risk
“We will require substantial future capital in order to complete planned and future clinical development for our lead product candidates” · word for word
30 Apr 2026DEF 14AProxy statement for 2026 annual meeting; routine proposals including election of directors and ratification of auditor.open
Figures in the filing · each found in the filing text
| Shares outstanding · 2026-04-24 | 78,520,587 |
30 Mar 20268-K · 2.02, 8.01Cash, cash equivalents and investments $247Mearningsopen
Figures in the filing · each found in the filing text
| Cash, cash equivalents and investments · Q4-2025 | $247M |
Risks flagged
Pre-revenue clinical-stage biotech with no approved products; dependent on clinical trial success and regulatory approvals.
“Clinical stage genetic medicine company; no revenue; net loss $26.1M.”
Clinical trial execution risk: LX2006 pivotal trial initiation in 1H 2026; LX2020 data in Q4 2026.
“Study initiation on track for 1H 2026; 12-month data update for all high dose participants in Q4 2026.” · word for word
30 Mar 202610-KNet loss $-100M (+2% y/y); Accumulated deficit $380M; Cash, cash equivalents, and investments in U.S. Treasury securities $247Mopen
Figures in the filing · each found in the filing text
| Net loss · FY2025 | $-100M | +2% y/y |
| Accumulated deficit · 2025-12-31 | $380M | |
| Cash, cash equivalents, and investments in U.S. Treasury securities · 2025-12-31 | $247M |
Risks flagged
No approved products; no revenue
“We have no products approved for commercialization and have never generated any revenue from product sales.” · word for word
Clinical trial failure risk
“Our business is dependent on our ability to advance our current and future product candidates through preclinical studies and clinical trials, obtain marketing approval and ultimately commercialize them. If we are unable to or experience significant delays in doing so, our business will be materially harmed.” · word for word
Capital needs
“We will require substantial future capital in order to complete planned and future clinical development for our lead product candidates, preclinical development for our other product candidates, and potential commercialization of these product candidates, if any are approved.” · word for word
5 Feb 20268-K · 5.02Reported a director or officer change (departure, election, appointment or pay arrangement)open
Risks flagged
Loss of key research leadership could impact pipeline execution.
“Dr. Adler stepped down as Head of Research; advisory role through July 2026.”
27 Jan 20268-K · 5.02Reported a director or officer change (departure, election, appointment or pay arrangement)open
Risks flagged
Loss of Dr. Adler as executive officer; transition to advisory role.
“Dr. Adler will no longer be an executive officer; remains senior clinical and scientific advisor.” · word for word
12 Jan 20268-K · 7.01, 8.01PKP2 protein expression increase (low dose) 93; PKP2 protein expression increase (high dose) 162; NSVT mean improvement (high dose) 22open
Figures in the filing · each found in the filing text
| PKP2 protein expression increase (low dose) · LX2020 low dose cohort · point_in_time | 93.0% | |
| PKP2 protein expression increase (high dose) · LX2020 high dose cohorts · point_in_time | 162.0% | |
| NSVT mean improvement (high dose) · LX2020 high dose cohorts · point_in_time | 22.0% | |
| PVC mean improvement (high dose) · LX2020 high dose cohorts · point_in_time | 14.0% |
Risks flagged
Clinical trial risk: small sample size (n=10), liver function test elevations observed, one Grade 3 SAE of sustained VT.
“Elevations in liver function tests observed in five participants at the high dose; one Grade 3 serious adverse event of sustained VT.”
5 Nov 202510-QLexeo Therapeutics reported Q3 2025 results with net loss of $79.0M YTD and cash of $122.8M, no revenue from product sales.earningsopen
Figures in the filing · each found in the filing text
| Net loss · Q3-2025 | $-79M | |
| Accumulated deficit · 2025-09-30 | $359M | |
| Cash, cash equivalents and investments in U.S. Treasury securities · 2025-09-30 | $123M |
Risks flagged
No approved products or revenue
“We have no products approved for commercialization and have never generated any revenue from product sales.” · word for word
Clinical trial failure risk
“Our business is dependent on our ability to advance our current and future product candidates through preclinical studies and clinical trials, obtain marketing approval and ultimately commercialize them. If we are unable to or experience significant delays in doing so, our business will be materially harmed.” · word for word
Novel gene therapy regulatory uncertainty
“Because gene therapy is novel and the regulatory landscape that governs any product candidates we may develop is rigorous, complex, uncertain and subject to change, we cannot predict with certainty the geographic areas in which we could obtain regulatory approval or the time and cost of obtaining regulatory approval, if we receive it at all, for any product ” · word for word
Capital needs and dilution risk
“We will require substantial future capital in order to complete planned and future clinical development for our lead product candidates, preclinical development for our other product candidates, and potential commercialization of these product candidates, if any are approved.” · word for word
5 Nov 20258-K · 2.02Cash, cash equivalents and investments (pre-financing) $123M; Equity financing gross proceeds $154M; LVMI mean improvement at 6 months 18earningsopen
Figures in the filing · each found in the filing text
| Cash, cash equivalents and investments (pre-financing) · Q3-2025 | $123M | |
| Equity financing gross proceeds · Q4-2025 | $154M | |
| LVMI mean improvement at 6 months · LX2006 · point_in_time | 18.0% | |
| LVMI mean improvement at 12 months · LX2006 · point_in_time | 23.0% | |
| mFARS mean improvement · LX2006 · point_in_time | $2.00 |
Risks flagged
Pre-revenue clinical-stage biotech with no approved products; dependent on clinical trial success and regulatory approvals.
“Clinical stage genetic medicine company; no revenue; net loss.”
Clinical trial execution risk: LX2006 pivotal trial initiation in 1H 2026; LX2020 data in January 2026.
“Plans to initiate a registrational study in the first half of 2026; LX2020 data update in January.” · word for word
Lexeo Therapeutics, Inc. — questions
- What did Lexeo Therapeutics, Inc. file recently?
- 16 SEC filings in the last 12 months. Latest: 8-K on 2026-09-29 — Completion of acquisition of Mantle Therapeutics Inc. for upfront consideration of $5.3M cash and $3M in Lexeo common stock, plus contingent payments up to $13M (additional cash $1M and milestone payments up to $12M over 12 years).
Every figure on this page comes from Lexeo Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.